Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.44
SYK's Cash to Debt is ranked higher than
59% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. SYK: 1.44 )
SYK' s 10-Year Cash to Debt Range
Min: 0.05   Max: 164.16
Current: 1.44

0.05
164.16
Equity to Asset 0.58
SYK's Equity to Asset is ranked higher than
62% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. SYK: 0.58 )
SYK' s 10-Year Equity to Asset Range
Min: 0.23   Max: 0.73
Current: 0.58

0.23
0.73
F-Score: 3
Z-Score: 4.62
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.92
SYK's Operating margin (%) is ranked higher than
86% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. SYK: 13.92 )
SYK' s 10-Year Operating margin (%) Range
Min: -5.63   Max: 23.92
Current: 13.92

-5.63
23.92
Net-margin (%) 11.15
SYK's Net-margin (%) is ranked higher than
84% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. SYK: 11.15 )
SYK' s 10-Year Net-margin (%) Range
Min: 0.92   Max: 17.39
Current: 11.15

0.92
17.39
ROE (%) 11.12
SYK's ROE (%) is ranked higher than
83% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. SYK: 11.12 )
SYK' s 10-Year ROE (%) Range
Min: 2.89   Max: 25.88
Current: 11.12

2.89
25.88
ROA (%) 6.39
SYK's ROA (%) is ranked higher than
80% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. SYK: 6.39 )
SYK' s 10-Year ROA (%) Range
Min: 0.75   Max: 15.1
Current: 6.39

0.75
15.1
ROC (Joel Greenblatt) (%) 44.79
SYK's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. SYK: 44.79 )
SYK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13.85   Max: 70.89
Current: 44.79

-13.85
70.89
Revenue Growth (%) 8.80
SYK's Revenue Growth (%) is ranked higher than
79% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. SYK: 8.80 )
SYK' s 10-Year Revenue Growth (%) Range
Min: 7.6   Max: 32.9
Current: 8.8

7.6
32.9
EBITDA Growth (%) -9.60
SYK's EBITDA Growth (%) is ranked higher than
67% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. SYK: -9.60 )
SYK' s 10-Year EBITDA Growth (%) Range
Min: -9.6   Max: 59.4
Current: -9.6

-9.6
59.4
EPS Growth (%) -6.20
SYK's EPS Growth (%) is ranked higher than
68% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. SYK: -6.20 )
SYK' s 10-Year EPS Growth (%) Range
Min: -43   Max: 153
Current: -6.2

-43
153
» SYK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

SYK Guru Trades in Q2 2013

Steven Cohen 43,966 sh (New)
Paul Tudor Jones 129,400 sh (+1802.94%)
Jim Simons 63,100 sh (+764.38%)
Ray Dalio 23,000 sh (+251.04%)
Jeremy Grantham 1,614,364 sh (+75.08%)
Chuck Royce 102,000 sh (+23.49%)
Joel Greenblatt 83,411 sh (+13.2%)
Ken Fisher 8,370 sh (+4.63%)
Donald Yacktman 12,088,680 sh (+0.16%)
Yacktman Fund 4,900,000 sh (unchged)
Vanguard Health Care Fund 1,433,500 sh (unchged)
PRIMECAP Management 304,500 sh (unchged)
Yacktman Focused Fund 5,100,000 sh (unchged)
Robert Olstein 108,000 sh (unchged)
» More
Q3 2013

SYK Guru Trades in Q3 2013

Jeremy Grantham 2,296,002 sh (+42.22%)
Jim Simons 86,500 sh (+37.08%)
Joel Greenblatt 112,529 sh (+34.91%)
Chuck Royce 113,800 sh (+11.57%)
Yacktman Fund 4,900,000 sh (unchged)
Robert Olstein 108,000 sh (unchged)
Yacktman Focused Fund 5,100,000 sh (unchged)
Vanguard Health Care Fund 1,433,500 sh (unchged)
PRIMECAP Management 304,500 sh (unchged)
Donald Yacktman 11,986,101 sh (-0.85%)
Ken Fisher 8,000 sh (-4.42%)
Ray Dalio 16,567 sh (-27.97%)
Steven Cohen 31,611 sh (-28.1%)
Paul Tudor Jones 8,900 sh (-93.12%)
» More
Q4 2013

SYK Guru Trades in Q4 2013

George Soros 450,000 sh (New)
Jim Simons 350,400 sh (+305.09%)
Ken Fisher 19,889 sh (+148.61%)
Paul Tudor Jones 13,610 sh (+52.92%)
Jeremy Grantham 2,636,722 sh (+14.84%)
Robert Olstein 108,000 sh (unchged)
PRIMECAP Management 304,500 sh (unchged)
Yacktman Fund 4,900,000 sh (unchged)
Yacktman Focused Fund 5,100,000 sh (unchged)
Vanguard Health Care Fund 1,433,500 sh (unchged)
Donald Yacktman 11,957,213 sh (-0.24%)
Chuck Royce 112,500 sh (-1.14%)
Steven Cohen 27,272 sh (-13.73%)
Ray Dalio 13,567 sh (-18.11%)
Joel Greenblatt 6,852 sh (-93.91%)
» More
Q1 2014

SYK Guru Trades in Q1 2014

Yacktman Fund 4,900,000 sh (unchged)
Yacktman Focused Fund 4,800,000 sh (-5.88%)
» More
» Details

Insider Trades

Latest Guru Trades with SYK

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Yacktman Focused Fund 2014-03-31 Reduce -5.88%0.24%$74.63 - $83.35 $ 79.050%4800000
George Soros 2013-12-31 New Buy0.29%$67.34 - $75.39 $ 79.058%450000
Joel Greenblatt 2013-12-31 Reduce -93.91%0.23%$67.34 - $75.39 $ 79.058%6852
Joel Greenblatt 2013-09-30 Add 34.91%0.06%$64.2 - $71.78 $ 79.0514%112529
Ray Dalio 2013-09-30 Reduce -27.97%$64.2 - $71.78 $ 79.0514%16567
Ray Dalio 2013-06-30 Add 251.04%0.01%$63.7 - $69.43 $ 79.0519%23000
Vanguard Health Care Fund 2013-03-31 New Buy0.37%$54.82 - $66.81 $ 79.0526%1433500
George Soros 2013-03-31 Sold Out 0.05%$54.82 - $66.81 $ 79.0526%0
Ray Dalio 2013-03-31 Reduce -91.6%0.04%$54.82 - $66.81 $ 79.0526%6552
Donald Yacktman 2012-12-31 Add 24.12%0.78%$52 - $56.57 $ 79.0547%12064853
Yacktman Fund 2012-12-31 Add 25.64%0.76%$52 - $56.57 $ 79.0547%4900000
Yacktman Focused Fund 2012-12-31 Add 14.41%0.55%$52 - $56.57 $ 79.0547%5100000
George Soros 2012-12-31 New Buy0.05%$52 - $56.57 $ 79.0547%75000
Ray Dalio 2012-12-31 Add 42.59%0.01%$52 - $56.57 $ 79.0547%78006
Donald Yacktman 2012-09-30 Add 73.95%1.4%$50.74 - $56.21 $ 79.0548%9720600
John Hussman 2012-09-30 Sold Out 0.52%$50.74 - $56.21 $ 79.0548%0
Joel Greenblatt 2012-09-30 Add 738.87%0.25%$50.74 - $56.21 $ 79.0548%76455
Ray Dalio 2012-09-30 Add 599.65%0.04%$50.74 - $56.21 $ 79.0548%54706
Mario Gabelli 2012-09-30 Sold Out 0.0038%$50.74 - $56.21 $ 79.0548%0
Joel Greenblatt 2012-06-30 Reduce -59.17%0.07%$49.7 - $55.99 $ 79.0548%9114
Ray Dalio 2012-06-30 Reduce -84.49%0.04%$49.7 - $55.99 $ 79.0548%7819
PRIMECAP Management 2012-06-30 Add 24.11%0.01%$49.7 - $55.99 $ 79.0548%304500
Mario Gabelli 2012-06-30 Reduce -48.1%$49.7 - $55.99 $ 79.0548%9275
John Hussman 2012-03-31 Reduce -33.33%0.2%$51.07 - $55.67 $ 79.0557%500000
Joel Greenblatt 2012-03-31 New Buy0.11%$51.07 - $55.67 $ 79.0557%22321
PRIMECAP Management 2012-03-31 New Buy0.02%$51.07 - $55.67 $ 79.0557%245344
Ray Dalio 2012-03-31 Reduce -26.19%0.01%$51.07 - $55.67 $ 79.0557%50419
Donald Yacktman 2011-12-31 Add 24.12%0.45%$45.35 - $50.18 $ 79.0564%5556837
Ray Dalio 2011-12-31 Reduce -26.79%0.02%$45.35 - $50.18 $ 79.0564%68306
Donald Yacktman 2011-09-30 Add 103.7%1.09%$43.8 - $60.6 $ 79.0554%4476966
Ray Dalio 2011-09-30 Add 128.12%0.04%$43.8 - $60.6 $ 79.0555%93300
Mario Gabelli 2011-09-30 Reduce -22.41%$43.8 - $60.6 $ 79.0554%22854
Mario Gabelli 2011-06-30 Add 81.2%0.01%$57.38 - $64 $ 79.0532%29454
John Hussman 2011-03-31 Reduce -40%0.51%$53.7 - $65.07 $ 79.0532%750000
Mario Gabelli 2011-03-31 Reduce -79.29%0.04%$53.7 - $65.07 $ 79.0532%16255
Joel Greenblatt 2011-03-31 Sold Out $53.7 - $65.07 $ 79.0532%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 30.10
SYK's P/E(ttm) is ranked higher than
56% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 26.70 vs. SYK: 30.10 )
SYK' s 10-Year P/E(ttm) Range
Min: 11.31   Max: 48.82
Current: 30.1

11.31
48.82
P/B 3.30
SYK's P/B is ranked higher than
56% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. SYK: 3.30 )
SYK' s 10-Year P/B Range
Min: 2.19   Max: 9.09
Current: 3.3

2.19
9.09
P/S 3.30
SYK's P/S is ranked lower than
54% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. SYK: 3.30 )
SYK' s 10-Year P/S Range
Min: 1.93   Max: 5.98
Current: 3.3

1.93
5.98
PFCF 17.70
SYK's PFCF is ranked higher than
83% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. SYK: 17.70 )
SYK' s 10-Year PFCF Range
Min: 11.63   Max: 65.41
Current: 17.7

11.63
65.41
EV-to-EBIT 23.30
SYK's EV-to-EBIT is ranked higher than
54% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. SYK: 23.30 )
SYK' s 10-Year EV-to-EBIT Range
Min: 6.8   Max: 31.6
Current: 23.3

6.8
31.6
PEG 11.70
SYK's PEG is ranked lower than
62% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. SYK: 11.70 )
SYK' s 10-Year PEG Range
Min: 0.5   Max: 16.73
Current: 11.7

0.5
16.73
Shiller P/E 24.80
SYK's Shiller P/E is ranked higher than
70% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 27.00 vs. SYK: 24.80 )
SYK' s 10-Year Shiller P/E Range
Min: 15.93   Max: 79.73
Current: 24.8

15.93
79.73

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.40
SYK's Dividend Yield is ranked higher than
60% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.28 vs. SYK: 1.40 )
SYK' s 10-Year Dividend Yield Range
Min: 0.15   Max: 1.66
Current: 1.4

0.15
1.66
Dividend Payout 0.42
SYK's Dividend Payout is ranked higher than
54% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 0.35 vs. SYK: 0.42 )
SYK' s 10-Year Dividend Payout Range
Min: 0.05   Max: 0.66
Current: 0.42

0.05
0.66
Dividend growth (3y) 20.40
SYK's Dividend growth (3y) is ranked higher than
88% of the 67 Companies
in the Global Medical Devices industry.

( Industry Median: 8.20 vs. SYK: 20.40 )
SYK' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 81.9
Current: 20.4

0
81.9
Yield on cost (5-Year) 12.28
SYK's Yield on cost (5-Year) is ranked higher than
99% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 1.39 vs. SYK: 12.28 )
SYK' s 10-Year Yield on cost (5-Year) Range
Min: 1.32   Max: 14.57
Current: 12.28

1.32
14.57
Share Buyback Rate 1.50
SYK's Share Buyback Rate is ranked higher than
92% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: -1.30 vs. SYK: 1.50 )
SYK' s 10-Year Share Buyback Rate Range
Min: 2   Max: -3.2
Current: 1.5

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.30
SYK's Price/Tangible Book is ranked lower than
78% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. SYK: 9.30 )
SYK' s 10-Year Price/Tangible Book Range
Min: 3.61   Max: 632.38
Current: 9.3

3.61
632.38
Price/DCF (Projected) 1.40
SYK's Price/DCF (Projected) is ranked higher than
79% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. SYK: 1.40 )
SYK' s 10-Year Price/DCF (Projected) Range
Min: 0.99   Max: 112.25
Current: 1.4

0.99
112.25
Price/Median PS Value 1.00
SYK's Price/Median PS Value is ranked higher than
73% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. SYK: 1.00 )
SYK' s 10-Year Price/Median PS Value Range
Min: 0.68   Max: 1.49
Current: 1

0.68
1.49
Price/Graham Number 3.50
SYK's Price/Graham Number is ranked lower than
62% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. SYK: 3.50 )
SYK' s 10-Year Price/Graham Number Range
Min: 1.5   Max: 36.14
Current: 3.5

1.5
36.14
Earnings Yield (Greenblatt) 4.30
SYK's Earnings Yield (Greenblatt) is ranked higher than
62% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. SYK: 4.30 )
SYK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.2   Max: 14.6
Current: 4.3

3.2
14.6
Forward Rate of Return (Yacktman) 1.31
SYK's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. SYK: 1.31 )
SYK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.8   Max: 42.3
Current: 1.31

1.8
42.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SMA, ZMH, STJ, EW » details
Traded in other countries:SYK.Germany
Stryker Corporation was incorporated in Michigan in 1946 as the successor company to a business founded in 1941. It is a medical technology company. The Company's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties. The Company's three reportable business segments are Reconstructive, MedSurg, and Neurotechnology and Spine. The Reconstructive segment includes orthopaedic reconstructive (hip and knee) and trauma implant systems as well as other related products. The MedSurg segment include surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical); reprocessed and remanufactured medical devices; as well as other medical device products used in a variety of medical specialties. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company's neurotechnology and Spine products include a comprehensive portfolio of products including both neurosurgical and neurovascular devices. Its neurotechnology offering includes products used for minimally invasive endovascular techniques, as well as a comprehensive line of products for traditional brain and open skull base surgical procedures, orthobiologic and biosurgery products including synthetic bone grafts and vertebral augmentation products, as well as minimally invasive products for the treatment of acute ischemic stroke. The Company also develops, manufactures and markets spinal implant products including cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. In the United States, most of the Company's products are marketed directly to doctors, hospitals and other health-care facilities. The Company's main competitors in neurotechnology are Covidien and Micrus Endovascular, LLC and in spine products are Medtronic Sofamor Danek, Inc., and DePuy Spine, Inc. The Company's businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide